Introduction: Advanced, persistent or recurrent cervical cancer in patients not amenable to curative surgery or radiotherapy predicts a dismal prognosis. Systemic chemotherapy based on paclitaxel/cisplatin ± bevacizumab is the current standard of care. However, once progression occurs, the possibility of alternative treatment options is very limited. Areas covered: The usefulness of capecitabine has been well-established against several cancer types, including head and neck, breast, and colorectal cancer. This review covers current literature evidence on the clinical efficacy and safety of capecitabine in cervical cancer treatment, either as monotherapy or combined with other agents or chemo-radiotherapy. Expert opinion: Recent clinical data, albeit scant, suggested a promising role for capecitabine both as monotherapy in patients with platinum-resistant cervical cancer and in combination with cisplatin in chemotherapy-naïve patients with metastatic or recurrent cervical cancer. In our opinion, capecitabine, especially in combination regimens, could represent a valid treatment option and further research is warranted to better understand its effectiveness in these challenging patients.

Capecitabine in treating patients with advanced, persistent, or recurrent cervical cancer: an active and safe option? / Tomao, F.; Caruso, G.; Musacchio, L.; Di Donato, V.; Petrella, M. C.; Verrico, M.; Tomao, S.; Benedetti Panici, P.; Muzii, L.; Palaia, I.. - In: EXPERT OPINION ON DRUG SAFETY. - ISSN 1474-0338. - 20:6(2021), pp. 641-650. [10.1080/14740338.2021.1887850]

Capecitabine in treating patients with advanced, persistent, or recurrent cervical cancer: an active and safe option?

Tomao F.
Primo
;
Caruso G.
Secondo
;
Musacchio L.;Di Donato V.;Verrico M.;Tomao S.;Benedetti Panici P.;Muzii L.
Penultimo
;
Palaia I.
Ultimo
2021

Abstract

Introduction: Advanced, persistent or recurrent cervical cancer in patients not amenable to curative surgery or radiotherapy predicts a dismal prognosis. Systemic chemotherapy based on paclitaxel/cisplatin ± bevacizumab is the current standard of care. However, once progression occurs, the possibility of alternative treatment options is very limited. Areas covered: The usefulness of capecitabine has been well-established against several cancer types, including head and neck, breast, and colorectal cancer. This review covers current literature evidence on the clinical efficacy and safety of capecitabine in cervical cancer treatment, either as monotherapy or combined with other agents or chemo-radiotherapy. Expert opinion: Recent clinical data, albeit scant, suggested a promising role for capecitabine both as monotherapy in patients with platinum-resistant cervical cancer and in combination with cisplatin in chemotherapy-naïve patients with metastatic or recurrent cervical cancer. In our opinion, capecitabine, especially in combination regimens, could represent a valid treatment option and further research is warranted to better understand its effectiveness in these challenging patients.
2021
5-fluorouracil; capecitabine; chemotherapy; metastatic cervical cancer; recurrent cervical cancer
01 Pubblicazione su rivista::01a Articolo in rivista
Capecitabine in treating patients with advanced, persistent, or recurrent cervical cancer: an active and safe option? / Tomao, F.; Caruso, G.; Musacchio, L.; Di Donato, V.; Petrella, M. C.; Verrico, M.; Tomao, S.; Benedetti Panici, P.; Muzii, L.; Palaia, I.. - In: EXPERT OPINION ON DRUG SAFETY. - ISSN 1474-0338. - 20:6(2021), pp. 641-650. [10.1080/14740338.2021.1887850]
File allegati a questo prodotto
File Dimensione Formato  
Tomao_Capecitabine in treating_2021.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 1.49 MB
Formato Adobe PDF
1.49 MB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1551505
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact